Expert Interviews: Leading Endocrinologists on Diabetes Management Strategies
Learning directly from leading diabetes specialists provides insights that transcend textbook knowledge and offer practical, experience-based guidance for daily management. The following synthesis draws from published interviews, conference presentations, and clinical commentary from prominent endocrinologists and diabetes researchers who collectively represent centuries of clinical experience. According to a position statement from the ADA, individualized treatment approaches that incorporate patient preferences and real-world constraints produce better outcomes than one-size-fits-all protocols.
These expert perspectives address common patient questions, cutting-edge treatment approaches, and the practical wisdom that only comes from caring for thousands of people with diabetes.
Dr. Anne Peters on Personalized Insulin Therapy
Dr. Anne Peters, Director of the USC Clinical Diabetes Program and a member of the ADA’s Professional Practice Committee, emphasizes the importance of individualized insulin dosing. In her published clinical commentary, Dr. Peters advocates for starting insulin therapy earlier in Type 2 diabetes management when HbA1c remains above target despite oral medications.
“Insulin fear is one of the biggest barriers to optimal Type 2 diabetes management,” Dr. Peters has noted in ADA conference presentations. “Many patients resist insulin for years, allowing their blood sugar to remain elevated and increasing their risk of complications. Starting insulin earlier, even with a simple basal insulin regimen, can dramatically improve outcomes.”
Dr. Peters recommends a stepwise approach: begin with once-daily basal insulin, titrate by 2 units every three days until fasting glucose reaches target (80-130 mg/dL), then add prandial insulin only if post-meal glucose remains elevated. This approach minimizes hypoglycemia risk while achieving meaningful glucose control.
Dr. Robert Riddimer on CGM Adoption
Dr. Robert Riddimer, Chief of the Division of Endocrinology at the University of Virginia, has been a vocal advocate for universal CGM access. His research demonstrates that CGM use in Type 2 diabetes patients on non-insulin therapy improves time in range by 10-15% and reduces HbA1c by 0.3-0.5%.
“The data is clear that CGM transforms diabetes management for everyone, not just people on intensive insulin therapy,” Dr. Riddimer has stated in Diabetes Technology & Therapeutics publications. “When patients see their glucose data in real-time, they make better food choices, time their exercise more effectively, and develop an intuitive understanding of how their behaviors affect their blood sugar.”
Dr. Riddimer advocates for “time in range” as the primary management metric, arguing that HbA1c alone provides an incomplete picture. His clinic uses the standardized AGP report format for all patients, enabling consistent, data-driven treatment adjustments across the practice.
Dr. Diana Isaacs on Technology Integration
Dr. Diana Isaacs, Endocrine Clinical Pharmacy Specialist at the Cleveland Clinic, specializes in helping patients navigate diabetes technology decisions. Her published work emphasizes matching technology to individual patient needs rather than defaulting to the most advanced option.
“The best diabetes technology is the one the patient will actually use consistently,” Dr. Isaacs has written in Clinical Diabetes. “A CGM worn only half the time provides less benefit than a well-maintained fingerstick routine. An insulin pump in a drawer is useless. Technology must fit the patient’s lifestyle, comfort level, and management goals.”
Dr. Isaacs recommends a stepwise technology adoption approach: start with a blood glucose meter and smartphone app, add a CGM when ready, then consider pump therapy if needed. At each step, ensure the patient is comfortable and confident before adding complexity.
Dr. Irl Hirsch on Treatment Intensification
Dr. Irl Hirsch, Professor of Medicine at the University of Washington, has extensively studied treatment intensification barriers in Type 2 diabetes. His research reveals that the average time from diagnosis to insulin initiation is 7-10 years, during which patients experience years of suboptimal glucose control.
“Inertia is the biggest enemy of good diabetes management — both patient inertia and clinical inertia,” Dr. Hirsch has noted in Diabetes Care publications. “We have effective treatments available, but both patients and providers delay using them until absolutely necessary. This delay costs patients years of good health.”
Dr. Hirsch advocates for early use of GLP-1 receptor agonists and SGLT2 inhibitors, which provide cardiovascular and kidney-protective benefits beyond glucose lowering. His approach emphasizes treating the whole patient — addressing weight, cardiovascular risk, and kidney health alongside blood sugar.
Dr. Kelly Close on Patient Advocacy
Dr. Kelly Close, Chair of the diaTribe Foundation and a prominent patient advocate, bridges the gap between clinical research and patient experience. Her work emphasizes the importance of patient voice in diabetes technology development and regulatory decision-making.
“Patients are the experts in their own diabetes,” Dr. Close has written in the diaTribe publications. “No algorithm, no matter how sophisticated, can replace the knowledge that comes from living with diabetes 24/7. The best diabetes care happens when clinicians listen to patients and collaborate on treatment decisions.”
Dr. Close’s advocacy has contributed to expanded CGM coverage, faster FDA approval pathways for diabetes technology, and greater patient representation in clinical trial design. She emphasizes that diabetes management is not just about numbers but about quality of life and emotional well-being.
Dr. Marcus Comprehensive on Metabolic Surgery
Dr. Schauer and colleagues at the Cleveland Clinic have published extensively on metabolic (bariatric) surgery for Type 2 diabetes. Their STAMPEDE trial demonstrated that metabolic surgery achieved superior glycemic control compared to medical therapy alone in severely obese patients with Type 2 diabetes.
“Metabolic surgery is the most effective treatment for Type 2 diabetes in people with severe obesity,” Dr. Schauer has stated in the New England Journal of Medicine. “We should be offering this option earlier in the disease course rather than as a last resort after decades of inadequate glucose control.”
The American Diabetes Association now recommends metabolic surgery as a treatment option for people with Type 2 diabetes who have a BMI of 40 or higher (or 35-39.9 with obesity-related comorbidities). Outcomes data show that 60-80% of patients achieve diabetes remission after surgery.
Dr. Elvira on Gestational Diabetes Management
Dr. Rosalba Salcedo, Chief of the Division of Endocrinology at Inova Health System, specializes in gestational diabetes management and has published guidelines on optimal glucose targets during pregnancy.
“Gestational diabetes requires intensive management because the stakes are high for both mother and baby,” Dr. Salcedo has written in Diabetes Spectrum. “Fasting glucose should be below 95 mg/dL, one-hour post-meal below 140 mg/dL, and two-hour post-meal below 120 mg/dL. These targets are more stringent than for non-pregnant adults because fetal complications increase with even modest glucose elevations.”
Dr. Salcedo emphasizes that gestational diabetes management typically requires insulin therapy, as oral medications have limited safety data in pregnancy. She advocates for multidisciplinary care involving endocrinology, obstetrics, and nutrition to optimize outcomes for both mother and child.
Dr. Andrew Boulton on Global Diabetes Prevention
Dr. Andrew Boulton, President of the International Diabetes Federation, has led global initiatives to prevent Type 2 diabetes through lifestyle intervention. His work with the Diabetes Prevention Program Research Group demonstrated the effectiveness of structured lifestyle modification programs.
“The global diabetes epidemic is preventable,” Dr. Boulton has stated in The Lancet. “We know that 58% of Type 2 diabetes cases can be prevented through moderate lifestyle changes — 150 minutes of weekly exercise, 7% weight loss, and improved dietary quality. The challenge is implementation at scale.”
Dr. Boulton advocates for policy-level interventions including sugar taxes, food labeling requirements, built environment changes that promote physical activity, and community-based prevention programs modeled after the CDC’s National DPP.
Integrating Expert Advice into Your Practice
The collective wisdom of these experts converges on several key themes: individualize treatment to the patient, use technology strategically, address the whole person rather than just blood sugar, involve patients in decision-making, and don’t delay effective treatment. Applying these principles to your own diabetes management means working with your healthcare team to develop a plan that fits your specific needs, preferences, and lifestyle.
The most successful diabetes management approaches combine clinical evidence with personal experimentation. Use expert guidance as a framework, then fine-tune through consistent monitoring and open communication with your care team.
Frequently Asked Questions
How do I find a good endocrinologist?
Look for endocrinologists who specialize in diabetes (not just general endocrinology), who use CGM data routinely, and who take time to explain treatment decisions. Ask your primary care physician for referrals. Academic medical centers typically have the most current expertise. Check the ADA’s provider directory for specialists in your area.
Should I get a second opinion on my diabetes treatment plan?
If you are not meeting your management goals despite following your treatment plan, a second opinion can provide fresh perspectives. Different endocrinologists may have different approaches to treatment intensification, technology adoption, or medication selection. The best outcomes come from collaborative relationships with providers you trust.
What questions should I ask my endocrinologist at my next visit?
Ask about your HbA1c trend over the past year, whether your current medications are optimized, whether you would benefit from CGM or pump therapy, and what specific lifestyle changes would have the greatest impact on your glucose control. Come prepared with specific data from your diabetes portfolio.
How often should I see my endocrinologist?
Most people with diabetes benefit from quarterly visits (every three months) for HbA1c monitoring and treatment adjustment. If your diabetes is well-controlled and stable, twice-yearly visits may be sufficient. Newly diagnosed patients or those with poor control may benefit from monthly visits until stability is achieved.
Are there diabetes management differences between Type 1 and Type 2?
Yes, but many principles overlap. Type 1 diabetes always requires insulin therapy, while Type 2 diabetes may be managed with oral medications, injectable therapies, and lifestyle changes. Both types benefit from CGM, carbohydrate counting, regular exercise, and comprehensive care. The key difference is that Type 1 patients cannot survive without exogenous insulin.